-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On November 1, Allis Pharmaceuticals announced that its third-generation EGFR-TKI drug Ivesa (Vometinib mesylate) is the first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive EGFR mutations.
The multi-center, randomized controlled, double-blind phase 3 clinical study (FURLONG) reached the primary endpoint of progression-free survival (PFS): Compared with the first-generation EGFR-TKI-treated control group, the vometinib treatment group showed significant Statistically significant and clinically significant progression-free survival benefit
.
The specific data results of the research will be officially announced at future international academic conferences
Vometinib is the third representative EGFR-TKI drug independently developed by Allis Pharmaceuticals, and it is planned to be developed for the treatment of advanced lung cancer
.
Clinical research data and clinical application results show that vometinib has a significant effect on people with lung cancer brain metastases, and its metabolites in the human body also have anti-tumor effects.
The FURLONG study is a randomized, double-blind, positive-controlled, multi-center phase 3 clinical study, which aims to compare vometinib mesylate (AST2818) with a reference drug (first-generation EGFR-TKI) in the first-line treatment of EGFR sensitive mutations.
The effectiveness and safety of patients with advanced or metastatic non-small cell lung cancer
.
The study was carried out in 55 research centers in China.
The main investigator of the FURLONG study, Professor Yuankai Shi from the National Cancer Center/Tumor Hospital of the Chinese Academy of Medical Sciences, pointed out that there are still unmet needs for the first-line treatment of NSCLC patients with EGFR gene-sensitive mutations; as the specific data of the FURLONG study is released in the future, it will be verified again.
Reference materials:
[1] Successful first-line study of third-generation EGFR-TKI vometinib in the treatment of advanced NSCLC.
